ATE289517T1 - Verwendung von glp-1 peptiden - Google Patents

Verwendung von glp-1 peptiden

Info

Publication number: ATE289517T1
Authority: AT; Austria
Prior art keywords: glp; peptides; satiety; appetite; analogue
Prior art date: 1996-11-12

Application number

AT97911155T

Other languages

English (en)

Inventor

Liselotte Bjerre Knudsen

Lars Thim

Martin Edward Judge

Jens Juul Holst

Arne Vernon Astrup

Brigitte Schjellerup Wulff

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-11-12

Filing date

1997-11-07

Publication date

2005-03-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8102971&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE289517(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-11-07 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2005-03-15 Application granted granted Critical

2005-03-15 Publication of ATE289517T1 publication Critical patent/ATE289517T1/de

Links

102400000322 Glucagon-like peptide 1 Human genes 0.000 title 1
102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
235000019789 appetite Nutrition 0.000 abstract 1
230000036528 appetite Effects 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
230000006698 induction Effects 0.000 abstract 1
230000002093 peripheral effect Effects 0.000 abstract 1
230000036186 satiety Effects 0.000 abstract 1
235000019627 satiety Nutrition 0.000 abstract 1
230000001629 suppression Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Hematology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Child & Adolescent Psychology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

AT97911155T 1996-11-12 1997-11-07 Verwendung von glp-1 peptiden ATE289517T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DK127096		1996-11-12
PCT/DK1997/000509 WO1998020895A1 (en)	1996-11-12	1997-11-07	Use of glp-1 peptides

Publications (1)

Publication Number	Publication Date
ATE289517T1 true ATE289517T1 (de)	2005-03-15

Family

ID=8102971

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT05002085T ATE366584T1 (de)	1996-11-12	1997-11-07	Verwendung von glp-1 peptiden
AT97911155T ATE289517T1 (de)	1996-11-12	1997-11-07	Verwendung von glp-1 peptiden

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT05002085T ATE366584T1 (de)	1996-11-12	1997-11-07	Verwendung von glp-1 peptiden

Country Status (9)

Country	Link
US (5)	US20030232754A1 (de)
EP (2)	EP1529534B1 (de)
JP (1)	JP2001504105A (de)
AT (2)	ATE366584T1 (de)
AU (1)	AU4863797A (de)
DE (2)	DE69732572T2 (de)
ES (2)	ES2290799T3 (de)
WO (1)	WO1998020895A1 (de)
ZA (1)	ZA9710182B (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6852690B1 (en)	1995-08-22	2005-02-08	Amylin Pharmaceuticals, Inc.	Method and composition for enhanced parenteral nutrition
UA65549C2 (uk)	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6380357B2 (en)	1997-12-16	2002-04-30	Eli Lilly And Company	Glucagon-like peptide-1 crystals
US6998387B1 (en)	1998-03-19	2006-02-14	Amylin Pharmaceuticals, Inc.	Human appetite control by glucagon-like peptide receptor binding compounds
US7223727B2 (en)	1998-04-09	2007-05-29	Serono Genetics Institute S.A.	GSSP4 polynucleotides and polypeptides and uses thereof
US6720407B1 (en) *	1998-08-28	2004-04-13	Eli Lilly And Company	Method for administering insulinotropic peptides
US6927214B1 (en)	1999-01-15	2005-08-09	Novo Nordisk A/S	Non-peptide GLP-1 agonists
US6514500B1 (en) *	1999-10-15	2003-02-04	Conjuchem, Inc.	Long lasting synthetic glucagon like peptide {GLP-!}
US9006175B2 (en)	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
DK1808438T3 (da)	1999-06-29	2014-10-27	Mannkind Corp	Rensning og stabilisering af peptid og proteiner i lægemidler
ATE381343T1 (de) *	1999-11-03	2008-01-15	Novo Nordisk As	Verwendung eines wachstumshormons oder eines wachstumshormon-sekretion fördernden mittels zur appetit-unterdrückung bzw. sättigungsinduktion
EP2213743A1 (de)	2000-04-12	2010-08-04	Human Genome Sciences, Inc.	Albuminfusionsproteine
AU5675701A (en) *	2000-05-16	2001-11-26	Sanwa Kagaku Kenkyusho Co	Agents for preventing or ameliorating insulin resistance and/or obesity
EP1357973B1 (de) *	2001-02-09	2008-08-20	Serono Genetics Institute S.A.	Gssp4-polynukleotide und -polypeptide sowie deren verwendung
CN100350968C (zh)	2001-09-24	2007-11-28	皇家创新有限公司	饮食行为的改进
WO2003059934A2 (en)	2001-12-21	2003-07-24	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2005003296A2 (en)	2003-01-22	2005-01-13	Human Genome Sciences, Inc.	Albumin fusion proteins
AU2002364586A1 (en)	2001-12-21	2003-07-30	Delta Biotechnology Limited	Albumin fusion proteins
PL209734B1 (pl)	2002-02-20	2011-10-31	Emisphere Tech Inc	Preparat farmaceutyczny zawierający związek GLP-1 i czynnik dostarczający oraz jego zastosowanie
WO2003080149A2 (en)	2002-03-20	2003-10-02	Mannkind Corporation	Inhalation apparatus
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP2298337B1 (de)	2003-12-09	2017-02-22	Novo Nordisk A/S	Regulierung des bevorzuchtes nahrungsaufnahmen mit verwendung von GLP-1 agonisten
US20060286129A1 (en)	2003-12-19	2006-12-21	Emisphere Technologies, Inc.	Oral GLP-1 formulations
HUE027902T2 (en)	2004-02-09	2016-11-28	Human Genome Sciences Inc Corp Service Company	Albumin fusion proteins
HRP20060362A2 (en)	2004-04-23	2007-03-31	Conjuchem Biotechnologies Inc.	Method for the purification of albumin conjugates
EP1758575A1 (de) *	2004-06-11	2007-03-07	Novo Nordisk A/S	Bekämpfung von arzneimittel-induzierter fettleibigkeit unter verwendung von glp-1-agonisten
PL1786784T3 (pl)	2004-08-20	2011-04-29	Mannkind Corp	Kataliza syntezy diketopiperazyn
KR101644250B1 (ko)	2004-08-23	2016-07-29	맨카인드 코포레이션	약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CN101258163B (zh)	2005-06-30	2013-08-21	益普生制药股份有限公司	Glp-1药物组合物
CN104324362B (zh)	2005-09-14	2018-04-24	曼金德公司	以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
DE602005017628D1 (de)	2005-09-22	2009-12-24	Biocompatibles Uk Ltd	Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz
US8039432B2 (en)	2005-11-09	2011-10-18	Conjuchem, Llc	Method of treatment of diabetes and/or obesity with reduced nausea side effect
EP2364735A3 (de)	2005-12-16	2012-04-11	Nektar Therapeutics	Verzweigte PEG-Kon jugate von GLP-1
IN2015DN00888A (de)	2006-02-22	2015-07-10	Mannkind Corp
EP1852108A1 (de)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	Zusammensetzungen von DPP-IV-Inhibitoren
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
EP2540725A1 (de)	2006-05-04	2013-01-02	Boehringer Ingelheim International GmbH	Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
EP1854455B1 (de)	2006-05-10	2009-10-07	Biocompatibles UK Limited	GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
CN101511868B (zh)	2006-07-24	2013-03-06	比奥雷克西斯制药公司	毒蜥外泌肽融合蛋白
TWI428346B (zh)	2006-12-13	2014-03-01	Imp Innovations Ltd	新穎化合物及其等對進食行為影響
EP2190872B1 (de)	2007-09-05	2018-03-14	Novo Nordisk A/S	Glucagon-like peptid-1-derivate und ihre pharmazeutische verwendung
US20100292133A1 (en)	2007-09-05	2010-11-18	Novo Nordisk A/S	Truncated glp-1 derivaties and their therapeutical use
US8785396B2 (en)	2007-10-24	2014-07-22	Mannkind Corporation	Method and composition for treating migraines
JP2011500850A (ja) *	2007-10-24	2011-01-06	マンカインドコーポレイション	Ｇｌｐ−１による副作用を防止する方法
WO2009055742A2 (en) *	2007-10-24	2009-04-30	Mannkind Corporation	Delivery of active agents
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
ES2929343T3 (es)	2008-06-13	2022-11-28	Mannkind Corp	Inhalador de polvo seco accionado por aspiración para la administración de fármacos
KR101628410B1 (ko)	2008-06-20	2016-06-08	맨카인드 코포레이션	흡입 활동에 관한 실시간 프로파일링을 위한 대화형 장치 및 방법
BRPI0916997A2 (pt)	2008-08-06	2020-12-15	Boehringer Ingelheim International Gmbh	Inibidor de dpp-4 e seu uso
TWI614024B (zh)	2008-08-11	2018-02-11	曼凱公司	超快起作用胰島素之用途
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
EP2216042A1 (de)	2009-02-09	2010-08-11	Ipsen Pharma S.A.S.	GLP1-analoge pharmazeutische Zusammensetzungen
DK2405963T3 (da)	2009-03-11	2013-12-16	Mannkind Corp	Apparat, system og fremgangsmåde til at måle modstand i en inhalator
CN104721825B (zh)	2009-06-12	2019-04-12	曼金德公司	具有确定比表面积的二酮哌嗪颗粒
US20120148586A1 (en)	2009-08-27	2012-06-14	Joyce Ching Tsu Chou	Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
WO2011056889A1 (en)	2009-11-03	2011-05-12	Mannkind Corporation	An apparatus and method for simulating inhalation efforts
KR20240090632A (ko)	2009-11-27	2024-06-21	베링거 인겔하임 인터내셔날 게엠베하	리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CN102946875A (zh)	2010-05-05	2013-02-27	贝林格尔.英格海姆国际有限公司	组合疗法
IL223742A (en)	2010-06-21	2016-06-30	Mannkind Corp	A dry powder inhaler and preparation for it
JP2013530993A (ja)	2010-07-02	2013-08-01	アンジオケムインコーポレーテッド	治療用コンジュゲートのための短く且つｄ−アミノ酸を含有するポリペプチドおよびその使用
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
SI2651398T1 (en)	2010-12-16	2018-04-30	Novo Nordisk A/S	SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
AU2012236150B2 (en)	2011-04-01	2016-03-31	Mannkind Corporation	Blister package for pharmaceutical cartridges
PL2696687T3 (pl)	2011-04-12	2017-06-30	Novo Nordisk A/S	Pochodne podwójnie acylowanej GLP-1
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
BR112014009686A2 (pt)	2011-10-24	2018-08-07	Mannkind Corp	composição analgésica inalável, pó seco e método para tratar dor
US20130172244A1 (en) *	2011-12-29	2013-07-04	Thomas Klein	Subcutaneous therapeutic use of dpp-4 inhibitor
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
PT2827845T (pt)	2012-03-22	2019-03-29	Novo Nordisk As	Composições compreendendo um agente de entrega e sua preparação
HRP20181447T1 (hr)	2012-03-22	2018-11-02	Novo Nordisk A/S	Pripravci glp-1 peptida i njihova priprava
JP6224084B2 (ja)	2012-05-14	2017-11-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6218811B2 (ja)	2012-05-14	2017-10-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6517690B2 (ja)	2012-06-20	2019-05-22	ノヴォノルディスクアー／エス	ペプチド及び送達剤を含む錠剤製剤
CN104619369B (zh)	2012-07-12	2018-01-30	曼金德公司	干粉药物输送系统和方法
US10159644B2 (en)	2012-10-26	2018-12-25	Mannkind Corporation	Inhalable vaccine compositions and methods
AU2014228415B2 (en)	2013-03-15	2018-08-09	Mannkind Corporation	Microcrystalline diketopiperazine compositions and methods
KR102272671B1 (ko)	2013-05-02	2021-07-06	노보 노르디스크 에이/에스	Glp-1 화합물의 경구 투여
SI3004155T1 (sl)	2013-05-28	2022-02-28	Takeda Pharmaceutical Company Limited	Peptidna spojina
MX375448B (es)	2013-07-18	2025-03-06	Mannkind Corp	Composiciones farmacéuticas en polvo seco estables al calor y métodos.
US11446127B2 (en)	2013-08-05	2022-09-20	Mannkind Corporation	Insufflation apparatus and methods
EP3110449B1 (de)	2014-02-28	2023-06-28	Boehringer Ingelheim International GmbH	Medizinische verwendung eines dpp-4-inhibitors
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
JP6995042B2 (ja)	2016-05-24	2022-02-04	武田薬品工業株式会社	ペプチド化合物
CN109310697A (zh)	2016-06-10	2019-02-05	勃林格殷格翰国际有限公司	利格列汀和二甲双胍的组合
JP6898518B2 (ja)	2018-02-02	2021-07-07	ノヴォノルディスクアー／エス	Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
CN113181346A (zh) *	2018-03-09	2021-07-30	上海仁会生物制药股份有限公司	用于治疗肥胖和体重管理的glp-1组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5118666A (en) *	1986-05-05	1992-06-02	The General Hospital Corporation	Insulinotropic hormone
US5120712A (en) *	1986-05-05	1992-06-09	The General Hospital Corporation	Insulinotropic hormone
US5418218A (en) *	1992-07-10	1995-05-23	The University Of Maryland At Baltimore	Histidyl-proline diketopiperazine (cyclo his-pro) a cns-active pharmacologic agent
US5380872A (en) *	1992-07-14	1995-01-10	Glaxo Inc.	Modulators of cholecystokinin
US5912229A (en) *	1996-03-01	1999-06-15	Novo Nordisk Als	Use of a pharmaceutical composition comprising an appetite-suppressing peptide
DE69740176D1 (de) *	1996-03-01	2011-05-26	Novo Nordisk As	Appetithemmendes Peptid, Zusammensetzung und Verwendung
US6458924B2 (en) *	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6268343B1 (en) *	1996-08-30	2001-07-31	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US7235627B2 (en) *	1996-08-30	2007-06-26	Novo Nordisk A/S	Derivatives of GLP-1 analogs
UA65549C2 (uk) *	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
DE122007000044I2 (de) *	1997-01-07	2011-05-05	Amylin Pharmaceuticals Inc	Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
ATE197408T1 (de) *	1998-01-30	2000-11-11	Novo Nordisk As	Eine injektionsspritze
US6420137B1 (en) *	1998-11-25	2002-07-16	American Home Products Corporation	Nucleic acid encoding human neurotensin subtype 2 receptor
US6528486B1 (en) *	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
US6399089B1 (en) *	2000-05-15	2002-06-04	A. Glenn Braswell	Compositions and methods for regulating metabolism and balancing body weight
US20020187926A1 (en) *	2001-03-07	2002-12-12	Knudsen Liselotte Bjerre	Combined use of derivatives of GLP-1 analogs and PPAR ligands
US7041646B2 (en) *	2001-10-05	2006-05-09	Bayer Pharmaceuticals Corporation	Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists

1997
- 1997-11-07 DE DE69732572T patent/DE69732572T2/de not_active Expired - Lifetime
- 1997-11-07 EP EP05002085A patent/EP1529534B1/de not_active Revoked
- 1997-11-07 JP JP52206198A patent/JP2001504105A/ja not_active Ceased
- 1997-11-07 DE DE69737916T patent/DE69737916T2/de not_active Revoked
- 1997-11-07 AU AU48637/97A patent/AU4863797A/en not_active Abandoned
- 1997-11-07 AT AT05002085T patent/ATE366584T1/de not_active IP Right Cessation
- 1997-11-07 EP EP97911155A patent/EP0941114B1/de not_active Expired - Lifetime
- 1997-11-07 AT AT97911155T patent/ATE289517T1/de not_active IP Right Cessation
- 1997-11-07 ES ES05002085T patent/ES2290799T3/es not_active Expired - Lifetime
- 1997-11-07 WO PCT/DK1997/000509 patent/WO1998020895A1/en not_active Ceased
- 1997-11-07 ES ES97911155T patent/ES2237790T3/es not_active Expired - Lifetime
- 1997-11-12 ZA ZA9710182A patent/ZA9710182B/xx unknown
2003
- 2003-03-06 US US10/382,438 patent/US20030232754A1/en not_active Abandoned
2007
- 2007-03-05 US US11/714,000 patent/US20070161568A1/en not_active Abandoned
2009
- 2009-02-12 US US12/370,308 patent/US20090149387A1/en not_active Abandoned
2010
- 2010-01-04 US US12/651,685 patent/US20100113363A1/en not_active Abandoned
- 2010-10-15 US US12/905,324 patent/US20110028391A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP0941114A1 (de)	1999-09-15
DE69737916D1 (de)	2007-08-23
EP1529534A2 (de)	2005-05-11
DE69732572T2 (de)	2005-12-29
EP0941114B1 (de)	2005-02-23
DE69732572D1 (de)	2005-03-31
WO1998020895A1 (en)	1998-05-22
ES2290799T3 (es)	2008-02-16
AU4863797A (en)	1998-06-03
ES2237790T3 (es)	2005-08-01
US20070161568A1 (en)	2007-07-12
JP2001504105A (ja)	2001-03-27
EP1529534A3 (de)	2005-06-08
DE69737916T2 (de)	2008-04-03
EP1529534B1 (de)	2007-07-11
ZA9710182B (en)	1998-05-12
US20090149387A1 (en)	2009-06-11
US20030232754A1 (en)	2003-12-18
US20110028391A1 (en)	2011-02-03
ATE366584T1 (de)	2007-08-15
US20100113363A1 (en)	2010-05-06

Legal Events

Date	Code	Title	Description
2005-08-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE289517T1 (de)	2005-03-15	Verwendung von glp-1 peptiden
NO940219D0 (no)	1994-01-21	Rekombinante antistoffer for human terapi
ATE306931T1 (de)	2005-11-15	Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
AU8402691A (en)	1992-03-17	Dental curing lamp and apparatus
EE04481B1 (et)	2005-06-15	Peptiididel ja adjuvantidel baseeruv farmatseutiline kompositsioon immuunmodulatsiooni jaoks
NO961796D0 (no)	1996-05-03	Rekombinante fedme (ob) proteiner
DK587589A (da)	1990-05-24	Sammensat kompressions- og stoetteforbinding og dens anvendelse samt deri indgaaende adhaesivmateriale
BG100974A (en)	1998-04-30	Vaccines against papillomavirus
ITRM910959A1 (it)	1993-06-19	Apparecchio e procedimento per la correzione dello sfalsamento in cc per un ricevitore.
ATE189480T1 (de)	2000-02-15	Rekombinantes avipoxvirus
EP0557455A4 (en)	1994-08-24	Recombinant feline coronavirus s proteins
EE04741B1 (et)	2006-12-15	Sigade sigimis- ja hingamissündroomi vaktsiin
HU9502573D0 (en)	1995-10-30	Recombinant adenoviruses and use thereof in gene therapy
DE69528531D1 (de)	2002-11-14	D-2-alkyltryptophan enthaltende polypeptide mit wachstumhormon freisetzender aktivitaet
AU7617791A (en)	1992-11-19	Recombinant immunocastration vaccine
DE69123345D1 (de)	1997-01-09	Sequenzielle c-termin degradierung von peptiden und proteinen
GR3036775T3 (en)	2002-01-31	Macroscopically oriented cell adhesion protein for wound treatment.
AU2623088A (en)	1989-11-03	New anti-receptor peptides and therapeutic agents
MX9205978A (es)	1993-04-01	Nuevas proteinas inhibidoras de trombina de garrapatas.
SG67924A1 (en)	1999-10-19	Recombinant antibodies for human therapy
EP0351017A3 (en)	1990-05-30	Pharmaceutical composition useful for the treatment of cardiovascular diseases
NZ333652A (en)	2000-07-28	Inhibition of human rotavirus infection using kappa-casein
AU1649592A (en)	1992-12-21	Recombinant immunocastration vaccine and polypeptides useful for same
SE9100284D0 (sv)	1991-01-30	Novel peptide
ITGE930058A1 (it)	1994-12-28	Circuito autoriscaldante per anestesia e rianimazione.